182133-25-1

Basic information

• Product Name: ARZOXIFENE
• Synonyms: ARZOXIFENE;2-(4-Methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol;Benzo[b]thiophene-6-ol, 2-(4-Methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-
• CAS NO: 182133-25-1
• Molecular Formula: C₂₈H₂₉NO₄S
• Molecular Weight: 475.606
• Mol File: 182133-25-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 174-176°
• Boiling Point: 656.4°Cat760mmHg
• Flash Point: 350.8°C
• Appearance: /
• Density: 1.234
• Vapor Pressure: 7.85E-18mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: ARZOXIFENE(CAS DataBase Reference)
• NIST Chemistry Reference: ARZOXIFENE(182133-25-1)
• EPA Substance Registry System: ARZOXIFENE(182133-25-1)

Safety Data

• Hazardous Substances Data: 182133-25-1(Hazardous Substances Data)

Usage

Uses

Arzoxifene is a selective estrogen receptor modulator. It is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.

Clinical Use

Arzoxifene is a third-generation SERM currently in Phase III clinical trials for the treatm ent of ER-positive recurrent/metastatic breast cancer. Similar to raloxifene, it is an ER antagonist in both breast and uterine tissues and an ER agonist on bone and the cardiovascular system. Arzoxifene is able to both preserve and build bone mineral density, which makes it a viable candidate for the treatment of osteoporosis. Ample evidence from early clinical trials indicates that arzoxifene also can be utilized as a chemopreventive agent against breast cancer.

Side effects

Adverse effects include hot flashes (major) and headache, nausea, vomiting, and constipation (minor).

InChI:InChI=1/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3

Upstream product

• 182133-23-9 [6-Benzyloxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-methoxyphenyl)]-benzo[b]thiophene 
• 182133-15-9 [6-benzyloxy-3-[4-(2-(piperidin-1-yl)ethoxy)phenoxy]-2-(4-methoxyphenyl)]benzo[b]thiophene-(S-oxide) 
• 225222-73-1 1-(4-bromophenyl)-2-(3-methoxyphenylsulfanyl)-ethanone 
• 15570-12-4 3-methoxybenzenethiol 
• 943439-55-2 6-methoxy-3-{4-[2-(1-piperidinyl)ethoxy]phenoxy}-2-(4-bromophenyl)benzo[b]thiophene S-oxide 
• 943439-54-1 3-bromo-2-(4-bromophenyl)-6-methoxy-1-oxidobenzothiophen-1-ium 
• 943439-53-0 6-methoxy-2-(4-bromophenyl)-3-bromobenzo[b]thiophene 
• 943439-52-9 2-(4-bromo-phenyl)-6-methoxy-benzo[b]thiophene 
• 943439-56-3 6-methoxy-3-{4-[2-(1-piperidinyl)ethoxy]phenoxy}-2-(4-bromophenyl)benzo[b]thiophene 
• 943439-50-7 4'-Bromo-4'-desmethoxyarzoxifene 
• 124-41-4 sodium methylate 

Downstream Products

• 195454-38-7 [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-methoxyphenyl)]benzo [b]thiophene-N-oxide 

Relevant articles and documents

PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE

The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of -CH2CH3 and phenyl; or R1 and R2/su

Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride

The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen dep

Treatment of central nervous system disorders with selective estrogen receptor modulators

The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of the formula in which R1 and R2 are independently hydroxy and alkoxy of one to four carbon atoms; and R3 and R4 are independently methyl or ethyl, or R3 and R4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.